Immuneering Reports Q2 2026 Financial Results and Key Updates
Immuneering Corp (IMRX) reported its Q2 2026 financials. The company announced positive interim Phase 2a pancreatic cancer data and is dosing patients in its pivotal Phase 3 MAPKeeper 301 trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day